VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
VolitionRx (NYSE AMERICAN: VNRX) has scheduled its Second Quarter 2025 Earnings Conference Call and Business Update for Friday, August 15, 2025, at 8:30 a.m. Eastern Time. The call will be hosted by key executives including Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and CEO), Terig Hughes (CFO), and Dr. Andrew Retter (Chief Medical Officer).
The conference call will be accessible via multiple channels, including toll-free numbers for U.S., Canada, and U.K. participants, as well as a live audio webcast. A replay will be available until August 29, 2025. The event will cover Q2 2025 financial results and provide updates on recent developments and upcoming milestones.
VolitionRx (NYSE AMERICAN: VNRX) ha programmato la sua Conferenza Telefonica sui Risultati del Secondo Trimestre 2025 e l'Aggiornamento Aziendale per venerd矛 15 agosto 2025, alle 8:30 ora della costa orientale. La chiamata sar脿 condotta da dirigenti chiave, tra cui Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (Presidente e CEO), Terig Hughes (CFO) e il Dr. Andrew Retter (Chief Medical Officer).
La conferenza sar脿 accessibile tramite diversi canali, inclusi numeri verdi per partecipanti negli Stati Uniti, Canada e Regno Unito, oltre a una diretta audio web. La registrazione sar脿 disponibile fino al 29 agosto 2025. L鈥檈vento tratter脿 i risultati finanziari del secondo trimestre 2025 e fornir脿 aggiornamenti sugli sviluppi recenti e le tappe future.
VolitionRx (NYSE AMERICAN: VNRX) ha programado su Conferencia Telef贸nica de Resultados del Segundo Trimestre de 2025 y Actualizaci贸n Empresarial para el viernes 15 de agosto de 2025 a las 8:30 a.m., hora del Este. La llamada ser谩 dirigida por ejecutivos clave, incluyendo a Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (Presidente y CEO), Terig Hughes (CFO) y el Dr. Andrew Retter (Chief Medical Officer).
La conferencia ser谩 accesible a trav茅s de m煤ltiples canales, incluyendo n煤meros gratuitos para participantes de EE. UU., Canad谩 y Reino Unido, as铆 como una transmisi贸n de audio en vivo por internet. La repetici贸n estar谩 disponible hasta el 29 de agosto de 2025. El evento cubrir谩 los resultados financieros del segundo trimestre de 2025 y ofrecer谩 actualizaciones sobre desarrollos recientes y pr贸ximos hitos.
VolitionRx (NYSE AMERICAN: VNRX)电� 2025雲� 8鞗� 15鞚� 旮堨殧鞚� 霃欕秬 響滌鞁� 鞓れ爠 8鞁� 30攵�鞐� 2025雲� 2攵勱赴 鞁れ爜 旎嵓霟办姢 旖� 氚� 靷梾 鞐呺嵃鞚错姼毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 旖滌潃 Louise Batchelor(攴鸽９ 斓滉碃 毵堨紑韺� 氚� 旎る雼堨紑鞚挫厴 毂呾瀯鞛�), Cameron Reynolds(靷灔 瓴� CEO), Terig Hughes(CFO), Dr. Andrew Retter(斓滉碃 鞚橂 毂呾瀯鞛�) 霌� 欤检殧 鞛勳洂霌れ澊 歆勴枆頃╇媹雼�.
旎嵓霟办姢 旖滌潃 氙戈淡, 旌愲倶雼�, 鞓侁淡 彀戈皜鞛愲ゼ 鞙勴暅 氍措 鞝勴檾氩堩樃鞕� 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼 霌� 雼れ枒頃� 毂勲剱鞚� 韱淀暣 鞝戩啀頃� 靾� 鞛堨姷雼堧嫟. 鞛箔旆ǖ鐢 2025雲� 8鞗� 29鞚�旯岇 臧�電ロ暕雼堧嫟. 鞚措矆 頄夓偓电� 2025雲� 2攵勱赴 鞛 瓴瓣臣鞕� 斓滉芳 歆勴枆 靸來櫓 氚� 頄ロ泟 欤检殧 鞚检爼鞐� 雽�頃� 鞐呺嵃鞚错姼毳� 雼る０ 鞓堨爼鞛呺媹雼�.
VolitionRx (NYSE AMERICAN: VNRX) a programm茅 sa conf茅rence t茅l茅phonique sur les r茅sultats du deuxi猫me trimestre 2025 et une mise 脿 jour commerciale pour le vendredi 15 ao没t 2025 脿 8h30, heure de l'Est. L'appel sera anim茅 par des cadres cl茅s, notamment Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (Pr茅sident et CEO), Terig Hughes (CFO) et le Dr Andrew Retter (Chief Medical Officer).
La conf茅rence t茅l茅phonique sera accessible via plusieurs canaux, y compris des num茅ros gratuits pour les participants des 脡tats-Unis, du Canada et du Royaume-Uni, ainsi qu'une diffusion audio en direct sur le web. La rediffusion sera disponible jusqu'au 29 ao没t 2025. L'茅v茅nement couvrira les r茅sultats financiers du deuxi猫me trimestre 2025 et fournira des mises 脿 jour sur les d茅veloppements r茅cents et les 茅tapes 脿 venir.
VolitionRx (NYSE AMERICAN: VNRX) hat seine Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 und ein Unternehmensupdate f眉r Freitag, den 15. August 2025, um 8:30 Uhr Eastern Time angesetzt. Die Telefonkonferenz wird von wichtigen F眉hrungskr盲ften geleitet, darunter Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (Pr盲sident und CEO), Terig Hughes (CFO) und Dr. Andrew Retter (Chief Medical Officer).
Die Telefonkonferenz ist 眉ber verschiedene Kan盲le zug盲nglich, darunter geb眉hrenfreie Nummern f眉r Teilnehmer aus den USA, Kanada und Gro脽britannien sowie ein Live-Audio-Webcast. Eine Aufzeichnung wird bis zum 29. August 2025 verf眉gbar sein. Die Veranstaltung behandelt die Finanzergebnisse des zweiten Quartals 2025 und gibt Updates zu aktuellen Entwicklungen und bevorstehenden Meilensteinen.
- None.
- None.
Conference call to take place on Friday, August 15 at 8:30 a.m.
Event:听听 VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call听
顿补迟别:听听听听 Friday, August 15, 2025
罢颈尘别:听听听 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 听13755349
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer and Dr. Andrew Retter, Chief Medical Officer. The call will provide an update on important events that have taken place in the second quarter of 2025 and upcoming milestones.
A live audio webcast of the conference call will also be available on this . In addition, a telephone replay of the call will be available until August 29, 2025. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.听 Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, [email protected] +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, [email protected] +1-212-915-2568
听
View original content:
SOURCE VolitionRx Limited
FAQ
When is VolitionRx's (VNRX) Q2 2025 earnings call scheduled?
How can investors access VolitionRx's Q2 2025 earnings call?
Who will be hosting VolitionRx's Q2 2025 earnings call?
Until when will the replay of VolitionRx's Q2 2025 earnings call be available?
